Use of a rare disease patient registry in long-term post-authorisation drug studies
The Lancet Respiratory Medicine in conversation with
English - May 04, 2018 23:00 - 9 minutes - 6.49 MBLife Sciences Science Education lungs pulmonary smoking vape flu Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: Primary graft dysfunction in lung transplantation
Next Episode: Cystic fibrosis
Dr. Diana Bilton joins The Lancet Respiratory Medicine to discuss how the use of rare disease patient registries helps with long term drug studies after drug authorisation.
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv